Akoya Biosciences, Inc. (AKYA)
2025-03-31 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenue | 16,639 | 18,814 | 23,164 | |
| Cost of goods sold | 6,768 | 7,090 | 9,778 | |
| Gross profit | 9,871 | 11,724 | 13,386 | |
| Other restructuring costs | - | 1,690 | - | |
| Selling, general and administrative | 17,580 | 14,672 | 19,094 | |
| Research and development | 5,557 | 4,474 | 5,288 | |
| Change in fair value of contingent consideration | 146 | -763 | 88 | |
| Total operating expenses | 23,283 | 20,073 | 24,470 | |
| Loss from operations | -13,412 | -8,349 | -11,084 | |
| Interest expense | -2,492 | -2,625 | -2,606 | |
| Interest income | 313 | 521 | 668 | |
| Other expense, net | -13 | -36 | -80 | |
| Loss before provision for income taxes | -15,604 | -10,489 | -13,102 | |
| Provision for income taxes | 48 | 44 | 47 | |
| Net loss | -15,652 | -10,533 | -13,149 | |
| Basic eps | -0.32 | -0.21 | -0.27 | |
| Diluted eps | -0.32 | -0.21 | -0.27 | |
| Basic average shares | 49,664,515 | 49,503,272 | 49,419,982 | |
| Diluted average shares | 49,664,515 | 49,503,272 | 49,419,982 | |